Krajina: Spojené štáty
Jazyk: angličtina
Zdroj: NLM (National Library of Medicine)
AMIODARONE HYDROCHLORIDE (UNII: 976728SY6Z) (AMIODARONE - UNII:N3RQ532IUT)
Wockhardt Limited
AMIODARONE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE 50 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Amiodarone injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy. Amiodarone also can be used to treat patients with VT/VF for whom oral amiodarone is indicated, but who are unable to take oral medication. During or after treatment with amiodarone, patients may be transferred to oral amiodarone therapy [see Dosage and Administration (2)]. Use amiodarone for acute treatment until the patient's ventricular arrhythmias are stabilized. Most patients will require this therapy for 48 to 96 hours, but amiodarone may be safely administered for longer periods if necessary. Amiodarone is contraindicated in patients with: - Known hypersensitivity to any of the components of amiodarone, including iodine. Hypersensitivity reactions may involve rash, angioedema, cutaneous/mucosal hemorrhage (bleeding), fever, arthralgias (joint pains), eosinophilia (abnormal bl
Amiodarone Hydrochloride Injection, 50 mg/mL, is available, as follows: NDC 64679-739-01, 150 mg in 3 mL, single-dose vial, carton of 1 vial. NDC 64679-739-04, 150 mg in 3 mL, single-dose vial, carton of 5 vials. NDC 64679-739-02, 150 mg in 3 mL, single-dose vial, carton of 10 vials. NDC 64679-780-01, 900 mg/18 mL, multiple dose vial, carton of 1 vial. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Use carton to protect contents from light until used. This container closure is not made with natural rubber latex.
Abbreviated New Drug Application
AMIODARONE HYDROCHLORIDE- AMIODARONE HYDROCHLORIDE INJECTION WOCKHARDT LIMITED ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE AMIODARONE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR AMIODARONE INJECTION. AMIODARONE HCL INJECTION FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1985 INDICATIONS AND USAGE Amiodarone injection is an antiarrhythmic agent indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy. (1) DOSAGE AND ADMINISTRATION ● The recommended starting dose is about 1000 mg over the first 24 hours of therapy, delivered by the following infusion regimen (2): o Initial Load: 150 mg per 100 mL (in D W) infused over 10 minutes o Followed by: 1 mg/min for 6 hours o Followed by: 0.5 mg/min thereafter ● In the event of breakthrough episodes of VF or hemodynamically unstable VT (2): o Repeat the Initial Load described above as needed (infused over 10 minutes) ● Increase the rate of the maintenance infusion to achieve effective arrhythmia suppression. (2) DOSAGE FORMS AND STRENGTHS Injection, 50 mg/mL (3) CONTRAINDICATIONS Amiodarone is contraindicated in patients with (4): Known hypersensitivity to any of the components of amiodarone, including iodine Cardiogenic shock Marked sinus bradycardia Second- or third-degree atrio-ventricular (AV) block unless a functioning pacemaker is available. WARNINGS AND PRECAUTIONS Hypotension: Treat initially by slowing the infusion; additional standard therapy may be needed, including the following: vasopressor drugs, positive inotropic agents, and volume expansion_. _(5.1) Bradycardia and AV block: Treat by slowing the infusion rate or discontinuing amiodarone. (5.2) ADVERSE REACTIONS The most common adverse reactions (1-2%) leading to discontinuation of intravenous amiodarone therapy are hypotension, asystole/cardiac arrest/pulseless electrical Prečítajte si celý dokument